Posts by: Marta Figueiredo PhD

Marta Figueiredo PhD

Marta Figueiredo holds a master’s in evolutionary and developmental biology and a PhD in biomedical sciences from the University of Lisbon, Portugal. Her research is focused on the role of several signaling pathways in thymus and parathyroid glands embryonic development.

March 16, 2021March 16, 2021

Women with Huntington’s Experience Worse Symptoms Than Men, Global Study Suggests

News

Women with Huntington’s disease have worse motor, cognitive, and depressive symptoms than men with the condition, according to data from the global Enroll-HD observational study. Notably, no sex-specific differences were ... Read more

February 16, 2021February 17, 2021

Eurordis Survey: Healthcare Experience Worse for Rare Disease Patients

News, syndicated

People with rare disorders have a worse healthcare experience than those affected by chronic diseases, according to the results of an international survey conducted by Eurordis-Rare Diseases Europe. Indeed, rare ... Read more

February 9, 2021February 14, 2021

UK Guidelines Look to Better Mental Health of Huntington’s and Other Patients

News

The British Psychological Society has released evidence-based recommendations for health professionals managing the psychological health of people with Huntington’s disease and other neurodegenerative disorders. Its document noted the lack of research on psychological ... Read more

February 2, 2021February 2, 2021

More MOR1 May Contribute to Psychiatric, Motor Symptoms

News

Higher-than-normal levels of mu-opioid receptor 1 (MOR1) in the striatum — a brain region particularly affected in Huntington’s disease — may contribute to both early psychiatric symptoms and late motor ... Read more

November 26, 2020November 26, 2020

Survey Finds COVID-19 Disrupted Care, Well-Being of Rare Disease Patients in Europe

News, syndicated

The first wave of COVID-19 in Europe severely disrupted access to care and raised stress and anxiety in people with rare diseases, negatively affecting their health and well-being, according to a ... Read more

September 29, 2020September 29, 2020

Phase 3 Trial of Oral Pridopidine in Early Stage Patients Opening Soon

News

Prilenia Therapeutics, in partnership with the Huntington Study Group (HSG), has launched the Phase 3 PROOF-HD clinical trial to evaluate the company’s lead experimental oral therapy, pridopidine, in people with early ... Read more

September 15, 2020September 15, 2020

Huntington’s in Youth Closely Tied to Problems With School and Social Life

News

Behavioral changes due to early onset Huntington’s disease and problems with school, and social and family life are common, particularly among pediatric patients, according to a case series study in Germany. ... Read more

September 1, 2020September 1, 2020

Huntington’s Alters Brain Development Before Birth, Study Shows

News

Huntington’s disease alters nerve cell development in the cortex — a brain region largely affected in people with the condition — before birth, a study has found. “Huntington’s definitely has ... Read more

August 18, 2020August 18, 2020

Antidopaminergic Meds Ease Chorea But May Worsen Cognition, Study Finds

News

Antidopaminergic medications are associated with lesser chorea and irritability in people with Huntington’s disease, but they may worsen their cognitive skills, data from the largest observational study of the disease show. Future, prospective ... Read more

April 21, 2020August 25, 2020

Vaccinex’s Pepinemab Halts Brain Shrinkage, Eases Symptoms in Early Huntington’s Patients, Results Shows

News

Vaccinex’s experimental therapy pepinemab (VX15/2503) improves brain metabolism, halts its atrophy, and eases motor and cognitive symptoms in people with late prodromal (before clinical diagnosis) and early Huntington’s disease, according to initial ... Read more